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resistance to BRAF inhibition in melanoma
Amanda Lassen1, Mohammad Atefi1, Lidia Robert1, Deborah JL Wong1, Michael Cerniglia1,
Begonya Comin-Anduix2,4 and Antoni Ribas1,2,3,4,5*Abstract
Background: The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the
development of drug resistance. In this study we investigated whether co-targeting the MAPK and the PI3K-AKT
pathway can prevent emergence of resistance or provide additional growth inhibitory effects in vitro.
Methods: Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and GSK2141795B (AKTi)
in a panel of 23 BRAF mutated melanoma cell lines were evaluated on growth inhibition by an ATP-based
luminescent assay, on cell cycle and apoptosis by flow cytometry and on cell signaling by western blot. Moreover,
we investigated the possibilities of delaying or reversing resistance or achieving further growth inhibition by
combining AKTi with dabrafenib and/or the MEK inhibitor (MEKi) trametinib by using long term cultures.
Results: More than 40% of the cell lines, including PTEN-/- and AKT mutants showed sensitivity to AKTi
(IC50 < 1.5 μM). The combination of dabrafenib and AKTi synergistically potentiated growth inhibition in the majority
of cell lines with IC50 > 5 nM dabrafenib. Combinatorial treatment induced apoptosis only in cell lines sensitive to
AKTi. In long term cultures of a PTEN-/- cell line, combinatorial treatment with the MAPK inhibitors, dabrafenib and
trametinib, and AKTi markedly delayed the emergence of drug resistance. Moreover, combining AKTi with the MAPK
inhibitors from the beginning provided superior growth inhibitory effects compared to addition of AKTi upon
development of resistance to MAPK inhibitors in this particular cell line.
Conclusions: AKTi combined with BRAFi-based therapy may benefit patients with tumors harboring BRAF
mutations and particularly PTEN deletions or AKT mutations.
Keywords: Melanoma, AKT inhibitor, Dabrafenib, Combination therapy, Drug resistanceIntroduction
BRAF inhibitors such as vemurafenib or dabrafenib ef-
ficiently block signaling downstream of the mutated
BRAFV600 protein, which initially results in profound
growth inhibition of the melanoma cells [1,2] and high
frequency of tumor regression in the clinic [3,4]. However,
the clinical use of these agents is limited by development
of acquired drug resistance [5]. Accumulating data suggest
that a single resistance mechanism does not account for
acquired resistance to BRAF inhibitors – instead a diverse* Correspondence: aribas@mednet.ucla.edu
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unless otherwise stated.array of mutations and signaling alterations has been de-
scribed. The best characterized core pathway resistance
mechanism is reactivation of the MAPK pathway. This
can be achieved by activating mutations in NRAS [6],
amplification of the BRAFV600 gene or truncations in the
BRAFV600 protein through alternative splicing resulting in
lack of inhibition by the drug due to increased dimerization
[7,8]. Activating mutations in MEK and overexpression
of the Ser/Thr MAP kinase kinase kinases (MAP3K8,
COT/Tpl2) has also been described in the context of
BRAF inhibitor resistance [9-11]. A common feature
for these MAPK reactivating resistance mechanisms is
that they bypass inhibition of BRAF and thereby restore
activation of ERK. Thus, blocking downstream MAPK
pathway at the level of MEK, alone or in combination
with BRAF inhibition could be a strategy to overcomeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.molecular-cancer.com/content/13/1/83this type of resistance and clinical trials addressing this
issue are already ongoing [12]. It is highly likely that
acquired resistance to the increasing use of dual BRAF
and MEK inhibition for the upfront treatment of pa-
tients with metastatic melanoma may lead to increased
reliance on MAPK-independent pathways during drug
escape [13,14]. In this setting, oncogenic signaling can
possibly be restored by enhanced signaling through the
PI3K-AKT pathway. Over-activity of the PI3K-AKT path-
way can be achieved by activating mutations in the signal-
ing molecules, deletion of the phosphatase and tensin
homolog (PTEN) or overexpression or over-activation
of receptor tyrosine kinases (RTKs) such as the platelet
derived growth factor beta (PDGFRβ) [6,15], the insulin-like
growth factor receptor-1 (IGFR-1) [16] or the epidermal
growth factor receptor (EGFR) [17] .
Given that the MAPK and the PI3K-AKT pathways are
the predominant signaling pathways in melanoma and that
MAPK-independent resistance to BRAF inhibitors can be
mediated through enhancement of signaling through the
PI3K-AKT pathway, it would be reasonable to combine a
BRAF inhibitor with an inhibitor of the PI3K-AKT pathway
to achieve synergistic antitumor activity [18-22]. This is fur-
ther supported by the fact that these two pathways are con-
nected in a complex network with extensive cross-talk and
feedback loops operating at different levels [13,23-28].
In this study, we tested the hypothesis that combining
the BRAF inhibitor dabrafenib, which recently has been
approved for clinical use by the US Food and Drug
Administration, with a novel AKT inhibitor tool com-
pound GSK2141795B (AKTi), which is an analogue of
the clinically tested AKT inhibitor GSK2141795, would
have superior anti-tumor effects in BRAFV600 mutant
melanoma cell lines compared to single agent dabrafe-
nib. Furthermore, we investigated whether addition of
the AKTi upon resistance to MAPK inhibitors could pro-
vide secondary responses, and whether upfront combin-
ation of dabrafenib, trametinib and AKTi could delay the
emergence of drug resistance. Here we provide evidence
that the combination of dabrafenib and AKTi synergistic-
ally inhibits proliferation in the majority of cell lines tested.
Furthermore, we show that AKTi can delay the emergence
of resistance to MAPK inhibitors and also provide further
growth inhibition upon resistance to a combination of
MAPK inhibitors in the only AKTi sensitive cell line
tested in this study.
Results
Effects of single agent dabrafenib or AKTi on cell growth
and cell signaling
In this study, a panel of 23 previously described [1,6]
melanoma cell lines harboring BRAFV600 mutations
(Table 1) was used to assess the effects of targeting the
MAPK pathway and the PI3K-AKT signaling pathway.The panel included 19 drug naïve cell lines and four
sub-lines (M229AR, M238AR, M397AR and M409AR)
with acquired resistance to the BRAF inhibitor vemurafe-
nib developed by continuous in vitro exposure to this drug
[13]. The MAPK pathway was inhibited by the BRAF
inhibitor dabrafenib and the PI3K-AKT pathway was inhib-
ited by the AKT inhibitor GSK2141795B (AKTi). By per-
forming growth assays (Additional file 1: Figure S1A) and
arranging cell lines according to their IC50 values a cut-off
of 100 nM for resistance to dabrafenib as single drug was
determined on the basis of the natural gap in the IC50
values (Figure 1A). This divided the cell lines into two
groups: sensitive (IC50 < 100 nM, 43%, 10 out of 23) and
resistant (IC50 > 100 nM, 57%, 13 out of 23) to dabrafe-
nib. The sensitive group could further be divided into
two groups: very sensitive (IC50 < 1 nM) and sensitive
(1 nM < IC50 < 100 nM). In 8 out of the 13 resistant cell
lines (from M308 and to the right in Figure 1A), the
IC50 was not achieved in the tested concentration range
(e.g. IC50 < 10 μM). Based on the inhibitory effects of single
agent AKTi and according to the calculated IC50 values for
this inhibitor, cells lines were divided into three groups
(Figure 1B): sensitive (IC50 < 1.5 μM), intermediate resistant
(1.5 μM< IC50 < 5 μM) and resistant (IC50 > 5 μM). PTEN
is a known negative regulator of the PI3K-AKT pathway
and lack of expression or mutations in the protein can
cause over activity of this pathway. Interestingly, most of
the PTEN null cell lines were among the AKTi sensitive cell
lines including M249, M411, M399, M397 and M397AR,
indicated with red bars. However, M233 has homozygous
PTEN loss but was less sensitive to AKTi. The only known
AKT mutant in this series, M262 (AKT1E17K), was also
found in the sensitive group (blue bar).
The efficacy of the drugs in inhibiting the signaling
pathways was verified by western blot analysis of phosphor-
ylated proteins (Figure 1C and 1D). Dabrafenib caused a
clear reduction in p-MEK, p-ERK and p-S6 at a concen-
tration as low as 50 nM in the dabrafenib sensitive cell
line M411, whereas such reductions were not evident in
the dabrafenib resistant cell line M299 (Figure 1C). AKTi
caused a concentration dependent decrease in p-S6, p-4E-
BP-1 and p-GSK-3β in the AKTi sensitive cell line M411.
On the contrary, in the AKTi resistant cell line M299,
AKTi only reduced p-GSK-3β (Figure 1D). In both cell
lines, both drugs induced p-AKTs, suggesting activation of
feedback mechanisms; however the induction of p-AKTs
was more pronounced by AKTi.
Combinatorial treatment with dabrafenib and AKTi
enhances cell growth inhibition in dabrafenib sensitive
and resistant cell lines
After evaluating the growth inhibition resulting from
treatment with each drug alone, we explored whether
blocking both pathways by the combination of dabrafenib
Table 1 Cell line characterization
BRAF Other oncogenic events
M229 BRAF V600E homozygous BRAF amp., AKT amp., PTEN heterozygous, MITF amp.
M229AR9 BRAF V600E homozygous BRAF amp., AKT amp., PTEN heterozygous, MITF amp.
M233 BRAF V600E heterozygous BRAF amp., AKT1 amp., CCND1 amp., EGFR amp., CDKN2A homo, PTEN null
M238 BRAF V600E heterozygous CDKN2A homozygous, PTEN heterozygous
M238AR BRAF V600E heterozygous CDKN2A homozygous, PTEN heterozygous
M249 BRAF V600E heterozygous BRAF amp., MITF amp., AKT2 amp., PTEN null
M255 BRAF V600E heterozygous AKT2 amp., CCND1 amp., EGFR amp., CDKN2A homozygous
M262 BRAF V600E homozygous AKT1 E17K, AKT amp., EGFR amp., CDKN2A homozygous
M263 BRAF V600E heterozygous CDKN2A heterozygous
M299 BRAF V600E heterozygous
M308 BRAF V600E heterozygous BRAF amp., MITF amp., AKT2 amp., EGFR amp., CDKN2A heterozygous
M370 BRAF V600E heterozygous
M397 BRAF V600E heterozygous PTEN null
M397AR BRAF V600E heterozygous PTEN null
M399 BRAF V600E heterozygous PTEN null
M406 BRAF V600E heterozygous N/T
M407 BRAF V600E heterozygous N/T
M409 BRAF V600E heterozygous N/T
M409AR BRAF V600E heterozygous N/T
M410 BRAF V600E heterozygous N/T
M411 BRAF V600E homozygous PTEN null
M414 BRAF V600K
M424 BRAF V600K
N/T: Not tested
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The IC50 values for the combination of the two drugs
(serial dilutions, in constant ratio to each other) were sig-
nificantly lower compared to the IC50 values for each
drug alone in the majority of cell lines sensitive and resist-
ant to dabrafenib (Figure 2A and 2B). A similar trend was
observed in the very sensitive group (Figure 2C). However,
due to the extreme sensitivity of these cells to dabrafenib,
additional growth inhibitory effect of AKTi was not as
pronounced. In the sensitive group, the reduction in IC50
values ranged from 81% (M249) to 89% (M263) compared
to the IC50 values for dabrafenib alone (Figure 2A). In the
dabrafenib resistant group, the IC50 for dabrafenib was
achieved in only four cell lines (e.g. IC50 > 10 μM). In these,
the reduction in IC50 values with the combined treatment
ranged from 73% (M397AR) to 93% (M255) (Figure 2B). In
order to determine whether the enhanced growth inhibi-
tory effects by the combined treatment were additive or
synergistic, combination index values (CI) for the com-
bination of the two drugs at IC50 were calculated by the
Chou-Talalal method. The CI values showed synergistic
effects (CI < 1) in all cell lines with a significant reduc-
tion in IC50 by the combined treatment (Figure 2D andAdditional file 1: Figure S1B). However, at IC75 four
(including M411 and M397) out of 5 cell lines in the very
sensitive group showed synergism (data not shown).
Basal levels of p-AKT in cell lines with differential sensitivity
to dabrafenib and AKTi
Next we evaluated the responses seen in growth assays
by quantitating basal levels of p-AKT in a representa-
tive panel of cell lines with differential sensitivity to
single agent dabrafenib or AKTi (Figure 3). The first panel
(Figure 3A + B) included 6 cell lines sensitive, 3 intermedi-
ate resistant and 5 cell lines resistant to AKTi. The data
shows that p-AKTSer473 levels seem to be associated with
responses to AKTi, where high level of p-AKT473 predicts
sensitivity to AKTi, though with exception of M233 and
M409AR. The second panel (Figure 3C + D) included 5
cell lines sensitive to dabrafenib and 7 cell lines resist-
ant to this inhibitor. Surprisingly, in this panel the re-
sistant cell lines did not express basal p-AKT473 at
higher level compared with the sensitive cell lines,
with the exception of M233. Moreover, in these panels,
cell lines M249, M399, M411, M397 and M233 did not
express PTEN.
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Figure 1 IC50 values of BRAFV600 mutated melanoma cells after exposure to single agent dabrafenib or AKTi and the effects of the
drugs on MAPK and the PI3K-AKT pathway. A panel of 23 BRAFV600 mutant human melanoma cell lines was treated with serial dilutions
(1-10,000 nM) of dabrafenib (A) or AKTi (B) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more
independent experiments in duplicates and the error bars represent the SEM. Western blot analysis of phosphorylated proteins in MAPK and the
PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib (C) or AKTi (D).
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http://www.molecular-cancer.com/content/13/1/83Changes in signaling through MAPK and PI3K-AKT pathways
upon treatment with combination of dabrafenib and AKTi
To further explore the effects of the two drugs, we selected
6 cell lines with differential sensitivity to single agent dabra-
fenib or AKTi (Table 2) and analyzed the impact on MAPK
and PI3K-AKT signaling after 24 hours of exposure to the
drugs either alone or in combination (Figure 4). In the
dabrafenib and AKTi sensitive cell line M411 there was
a clear reduction in p-S6, p-S6K, p-GSK-3β, p-MEK and
p-ERK with one or the other drug as single agent. Com-
bined treatment further reduced p-S6, p-GSK3-β, p-S6Kand p-4E-BP-1 in comparison with each single agent
treatment. In M397, single agent AKTi caused significant
reduction in p-S6 and by addition of dabrafenib only a
slight further decrease was achieved. The dabrafenib inter-
mediate resistant, AKTi sensitive cell line M414 showed
similar decreasing trends in p-S6 and p-GSK3-β, but
less pronounced than in M411. In the dabrafenib resist-
ant, AKTi intermediate sensitive cell line M410, AKTi
alone caused some decrease in p-S6 and the combination
resulted in further decrease. Noticeably, the presence of
AKTi either alone or in combination increased the level of
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Figure 2 Combination of dabrafenib with AKTi enhances cell growth inhibition in dabrafenib sensitive (A) and resistant cell lines (B)
but not in very sensitive cell lines (C). The cells were treated with increasing concentrations (1-10,000 nM) of single agent dabrafenib, single
agent AKTi or the combination (1:1) for 72-120 hours to assess cell viability. Bars represent the average IC50 value of two or more independent
experiments in duplicates and the error bars represent the SEM. (D) Combination index values (CI) for dabrafenib and AKTi. Values less than 1
indicates synergism, CI = 1 indicates an additive effect, and CI > 1 antagonism. The bars represent the average CI value of minimum two independent
experiments and the error bars represent the SEM. * p < 0.05 when single agent dabrafenib was compared to combination treatment.
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http://www.molecular-cancer.com/content/13/1/83p-S6K in this cell line. In the two cell lines resistant to
both drugs, M409AR and M299, a synergistic effect of
combined treatment, assessed by reduction in p-S6, was
observed only in M409AR. This finding is in agreement
with the fact that growth inhibition with combined treat-
ment of M409AR was superior to M299 (Additional file 1:
Figure S1A). Despite resistance to dabrafenib, a decrease in
p-MEK and p-ERK was seen in M410, M409AR and M299.
Overall, reduction in p-S6 seemed to be the hallmark of the
effects of single agent dabrafenib or AKTi or the combin-
ation (Additional file 2: Figure S2). In all the tested cell
lines, AKTi alone or in combination induced the level of
p-AKTs suggesting activation of a feedback mechanism.
Dabrafenib in combination with AKTi increases the subG1
population in AKTi sensitive cell lines and induces apoptosis
To investigate whether dabrafenib or AKTi or the com-
bination affect cell cycle, four representative cell lines
(M411, M414, M410 and M299) with different dabrafenib
and AKTi sensitivities (Table 2) were treated with DMSO(control) or either drug alone or in combination for
48 hours and stained with DAPI for cell cycle distribution
analysis by flow cytometry. As expected [1,29], single agent
dabrafenib compared with the control led to G0/G1 arrest,
regardless of the sensitivity to this drug, except in the more
resistant cell line M299 (Figure 5A). However, it should be
noticed that the increase in G0/G1 fraction in M414 did
not quite reach statistical significance (p = 0.055). AKTi as
single drug led to significant G0/G1 arrest only in the rela-
tively more AKTi sensitive cell line M411. The combined
treatment did not change the fraction of cells in G0/G1 in
any of the cell lines. More interesting, in the two AKTi
sensitive cell lines, M411 and M414, the combined treat-
ment resulted in a marked increase in the subG1 frac-
tion suggesting that this treatment induced apoptosis.
We further evaluated the apoptotic induction by detection
of cleaved-PARP, which is a marker of cells undergoing
late apoptosis [30,31] (Figure 5B). The cells were treated
as mentioned above and treatment with staurosporine
served as a positive control for apoptosis. Cells were
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Figure 3 Basal levels of p-AKT and PTEN status in cell lines with differential sensitivity to dabrafenib and AKTi. Phosphorylation of AKT
and PTEN status was determined by western blot analysis in a panel of cell lines with sensitivity or resistance to AKTi (A + B) or dabrafenib
(C + D). Quantitation of p-AKT was done by using image quant software. Total AKT and GAPDH served as loading controls.
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flow cytometry (Additional file 3: Figure S3). In agreement
with the noticed increase in subG1 fraction by cell cycle
analysis, combined treatment augmented apoptosis induc-
tion compared to single drug treatments only in the twoTable 2 Drug sensitivities of 6 selected cell lines
Dabrafenib AKTi
Resistance: IC50 > 100nM Resistance: IC50 > 1.5 μM
M411 Sensitive Sensitive
M397 Sensitive Sensitive
M414 Intermediate Sensitive
M410 Resistant Intermediate
M409AR Resistant Resistant
M299 Resistant ResistantAKTi sensitive cell lines M411 and M414. The induction
was relatively more pronounced in cell line M411, which
is sensitive to both drugs. These findings were confirmed
using a cell death detection ELISA kit (Additional file 4:
Figure S4).
Addition of AKTi upon development of resistance to MAPK
inhibitors can provide further growth inhibition in long term
culture of a sensitive cell line, while triple treatment from
the beginning delays the emergence of drug resistance
Whereas treatment with BRAF inhibitors at first results
in tumor regression in most patients, it is a well-known
fact that acquired drug resistance frequently develops
[32]. To prevent or delay development of resistance to
BRAFi, combinations of BRAFi and MEKi (MAPKi) are
in clinical testing [12]. However, development of resist-
ance to this MAPKi combination is predicted as well
Figure 4 Reduction of p-S6 with the combination of dabrafenib and AKTi in BRAFV600 mutated cell lines. Western blot analysis of the
effects of dabrafenib, AKTi or the combination on MAPK and the PI3K-AKT pathway in six representative BRAFV600 mutated cell lines with differential
sensitivity to single agent AKTi and dabrafenib (Table 2). The analysis was performed after 24 hours exposure to DMSO (control), dabrafenib (50 nM),
AKTi (2.5 μM) or the combination.
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http://www.molecular-cancer.com/content/13/1/83and addition of AKTi from the beginning or after the
emergence of resistance as an alternative option has been
suggested. By using long term in vitro culture as a model,
we explored whether addition of AKTi upon emergence
of resistance to dabrafenib in combination with the
MEKi, trametinib, could provide further growth inhibition
(Figure 6 A + B). The AKTi/MAPKi sensitive PTEN-/- cell
line M397 and the AKTi/MAPKi resistant cell line M299
were cultured in 96-well plates in the presence of 200 nM
dabrafenib in combination with 2 nM trametinib. Initially,
growth of M397 was inhibited; after 7 days of culture a
70% reduction in cell number was achieved (Figure 6A).
After a short period of 4-5 weeks the cells started to pro-
liferate despite the presence of the drugs. On day 41, tra-
metinib was replaced with 2.5 μM AKTi, which resulted
in marked additional growth inhibition and decrease in
cell numbers. As expected, from the beginning M299 con-
tinued growing despite the presence of the MAPK inhibi-
tors. Therefore the experiment was performed in a shorter
period of time with the switch from trametinib to AKTi on
day 5, which only caused some reduction in growth rate
(Figure 6B). Cell numbers were determined by an MTS-
based assay and use of a gradient with known number of
cells allowed the readout of each well to be calculated into
a quantitative cell number (Additional file 5: Figure S5).We then investigated whether a triple drug combin-
ation with AKTi, dabrafenib and trametinib from the
beginning could delay the emergence of resistance using
M397 in long term culture (Figure 6C). In this experi-
ment, we treated the cells with either 200 nM dabrafenib
as single drug or with 200 nM dabrafenib in combin-
ation with 2 nM trametinib or with 200 nM dabrafenib
in combination with 2 nM trametinib and 2.5 μM AKTi.
After 7 days of culture with dabrafenib alone or in
combination with trametinib, the number of cells was
reduced by 70%. However, despite the presence of the
MAPK inhibitors, the cells started proliferating and
within 41 days >12,000 cell/well on average were mea-
sured in the plates with single dabrafenib and in the
plates with dabrafenib in combination with trametinib.
Thus, addition of trametinib to dabrafenib did not
delay the development of drug resistance, suggesting a
non-MAPK pathway mechanism of resistance in this
PTEN null cell line. In contrast, triple treatment reduced
the cell number by >95% within 7 days. No signs of resist-
ance or regrowth were evident within 99 days of culture
with the triple inhibitor treatment which is in agreement
with our assumption regarding the role of AKT pathway
in resistance to MAPK inhibitors and possibility of using
AKTi to avoid resistance.
AB
Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 Combined treatment with dabrafenib and AKTi increases the subG1 fraction and induces apoptosis in cell lines sensitive to
AKTi as single agent. Four representative melanoma cell lines with differential sensitivity to single agent AKTi and dabrafenib (Table 2) were
cultured in DMSO (control), 1 μM staurosporine (positive control for apoptosis), 50 nM dabrafenib, 2.5 μM AKTi or the combination for 48 hours
and stained with DAPI for cell cycle analysis (A) and anti-cleaved-PARP for apoptosis analysis (B). Bars represent the average cell fractions of
minimum two independent experiments and the error bars represent the SEM. * p < 0.05 when comparing single agent dabrafenib with the
combination treatment.
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Co-targeting the MAPK and the PI3K-AKT pathway is
a compelling approach given the frequent cross-talk
and regulating feedback loops between these two pathways
[24,27]. Moreover, activation of the PI3K-AKT pathway has
been suggested to mediate resistance to MAPK inhibitors
[6,13,16,22,25,26], which strengthens the potential concept
of inhibiting both pathways simultaneously. In our series,
the single agent activity of the AKTi was more prominentDay 41:
Switch MEKi 
with AKTi
0
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r
M397 AKTi switch
Dabrafenib + trametinib Dabrafenib + AKTi
A
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C
Figure 6 Addition of AKTi upon development of resistance to MAPK
culture, while triple treatment from the beginning delays the emerge
cultured in 96-well plates in the presence of 200 nM dabrafenib in combin
replaced with AKTi (indicated by the arrow in the two cell lines respectivel
dabrafenib alone or in combination with 2 nM trametinib or in the presenc
Cell numbers were determined by a MTS-based assay and use of a gradien
to be calculated into a quantitative cell count (Additional file 5: Figure S5).
number in 60 well replicates for the plates treated with dabrafenib and train PTEN null cell lines and the only AKT mutant cell
line, while the antitumor activity of dabrafenib was not
negatively impacted by the presence of these alterations
in the PI3K-AKT pathway. Our studies show that com-
bining dabrafenib with AKTi had synergistic effects on
growth inhibition in the majority of BRAFV600 mutant
melanoma cell lines tested compared to single agent
treatments, regardless of their sensitivity to the individ-
ual agents. The cell lines that did not show synergistic0
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inhibitors can provide further growth inhibition in long term
nce of resistance. The PTEN -/- cell line M397 (A) and M299 (B) were
ation with 2 nM trametinib. On day 41 or day 5 trametinib was
y). (C) From day 0, M397 was cultured in the presence of 200 nM
e of triple drugs; 200 nM dabrafenib, 2 nM trametinib and 2.5 uM AKTi.
t with known number of cells which allowed the readout of each well
The cell number for each time point represents the average cell
metinib, and 120 replicate wells for the AKTi switch plates.
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single agent dabrafenib. The lack of synergism in this
group is likely due to the fact that 50% growth inhibition
was achieved at concentrations lower than 1 nM, which
was the lowest concentration in the dilution series used.
This makes the calculations of IC50 less reliable and an
extension of the lower concentration range would likely
result in measurable synergistic growth inhibitory effects.
In fact, in 4 out of the 5 cell lines in question showed syn-
ergistic effects at IC75 (data not shown).
The finding that PTEN null and other cell lines express-
ing high levels of p-AKTare among the dabrafenib sensitive
cell lines indicates that activation of the PI3K-AKT pathway
is probably not a reason for the innate resistance to BRAF
inhibition. Another explanation for this finding could be
that, although these cell lines are primarily dependent on
MAPK for their proliferation, they also to some extend
are dependent on PI3K-AKT pathway for their prolifera-
tion and survival. This idea can be supported by the fact
that in growth assays, these cell lines exhibit sensitivity to
both dabrafenib and AKTi as single agents, and the com-
bination treatment induced apoptosis in one tested PTEN
null cell line (M411). Other studies exploring dual inhib-
ition of the MAPK and the PI3K-AKT pathway using a
different panel of inhibitors also found that combinations
of MAPK and PI3-AKT pathway inhibitors augment induc-
tion of apoptosis in melanoma cells compared to single
drug treatments [19,33,34]. Moreover, in cell lines with high
levels of p-AKT, cell cycle analysis, apoptosis assay and long
term drug treatment assays indicate the importance of both
pathways and suggest that PI3K-AKT pathway gains higher
importance in long term presence of BRAF inhibitors and
during development of resistance to MAPK inhibitors.
In our studies, reduction in p-S6 seemed to be a good
predictor of sensitivity to either of the single drugs or
their combination. Reduction in p-S6 as a predictor of
response to RAF and MEK inhibitors has also been de-
scribed by others [35,36] and our data provides further
evidence for the alleged cross-talk between the two
pathways. Both sensitive and partially resistant cell lines to
either drug exhibited decrease in p-S6 with single drugs or
the combination, and a clear reduction was noticed in the
double-resistant cell line M409AR with the combinatorial
treatment. However, this was not observed in the cell line
M299, which is even more resistant to both drugs and
their combination. This suggests that reduction of p-S6
may be an indicator of response to either or dual targeting
of MAPK and the PI3K-AKT pathway.
In the study of AKTi’s effects on the PI3K-AKT path-
way, we observed a considerable increase in p-AKT at
both phosphorylation sites namely T308 and S473. This
induction suggests that the inhibition of AKT either
abrogates a negative feedback loop or induces a positive
regulation mechanism. Two different proteins have beenreported to be responsible for phosphorylation at site T308
and S473, PDK1 acting from upstream and mTORC2
acting from downstream of AKT, respectively. A well-
established feedback loop mediated by S6K inhibits the
PI3K-AKT pathway through phosphorylation and inactiva-
tion of insulin receptor substrate-1 (IRS1), which activates
PI3K [20,37]. Hence, inhibition of AKT would be expected
to decrease phosphorylation of downstream S6K, conse-
quently resulting in a feedback activation of PI3K with sub-
sequently PDK1 activation and increased pAKT308 levels.
However, in our study induction of pAKT308 was not con-
sistently accompanied by a decrease in p-S6K. This could
be explained by PDK1’s ability to phosphorylate S6K
directly [38], and an induction in p-S6K by AKTi was
in fact observed in M410.
Most patients with metastatic melanoma have early re-
sponse with BRAF inhibitors as monotherapy, but ac-
quired resistance frequently develops and the majority of
patients experience relapse with a median of 6-7 months
[4]. Supported by preclinical data showing that reactiva-
tion of the MAPK pathway often mediates acquired drug
resistance [39,40], the effects of combination therapy
with dabrafenib and the MEK inhibitor trametinib were
evaluated in a phase I/II trial. It was found that BRAFi/
MEKi combinatorial treatment improved the median
progression-free survival and increased the response rate
[12]. Though, as for monotherapy, resistance to the com-
bined therapy invariably develops. Work from a recent
publication by Wagle et. al suggest that most of the mech-
anisms of acquired resistance to combined BRAF and
MEK inhibitor therapy represent alterations which retain
the MAPK pathway active. Two of three reported MAPK
alterations had previously been described in the context of
resistance to RAF and MEK inhibitor monotherapy [41].
In addition to molecular changes in MAPK, genetic alter-
ations up-regulating the PI3K-AKT pathway have been
detected concurrently in the same tumor progressing on
MAPK inhibitor therapy [39]. This suggests that BRAFi/
MEKi combination therapy may lead to increased reliance
on MAPK-independent pathways such as the PI3K-AKT
pathway during drug escape. The results from our experi-
ment modeling this scenario showed that replacement of
trametinib with AKTi after the emergence of resistance to
the combination of dabrafenib and trametinib had consid-
erable growth inhibitory effects in the PTEN-/- AKTi sen-
sitive cell line, M397. After removal of trametinib one can
hypothesize that the melanoma cells would switch back to
depend on BRAF independent MAPK pathway signaling,
which naturally raises the thought of combining all
three inhibitors; dabrafenib, trametinib and AKTi. Using
the same cell line, our data demonstrates that triple
combinatorial treatment can delay the emergence of
drug resistance significantly. Cells cultured in the pres-
ence of dabrafenib and trametinib started re-growing
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signs of resistance and regrowth in the presence of all
three inhibitors within 99 days of culture.
Conclusion
Overcoming resistance to BRAFi is a major problem in
the treatment of metastatic melanoma. Multiple strategies
including combinatorial therapies are evaluated in the
attempt to solve this problem. Herein, we showed that
combining the BRAF inhibitor dabrafenib with an AKTi
potently inhibits growth in the majority of melanoma
cell lines tested and induces cell death in a subset of cell
lines. Moreover, AKT inhibition demonstrated ability to
reverse acquired drug resistance to combination therapy
with dabrafenib and trametinib in the single AKTi sensi-
tive cell line that was tested (M397). Finally, triple drug
administration delayed the emergence of drug resistance
in that particular cell line. Thus, combining dabrafenib
with an AKTi appears to be a promising strategy for more
effective treatment of melanoma. This is the basis of a US
cooperative group clinical trial (S1221, NCT 01902173),
which has the goal of determining the safety of the
combination of dabrafenib and the clinical grade AKTi
GSK2141795, and early evidence of the antitumor ac-
tivity of this combination in patients progressing on
prior BRAFi-based therapy.
Materials and methods
Reagents
Dabrafenib (GSK2118436A), trametinib (GSK1120212B)
and GSK2141795B (AKT inhibitor, AKTi) powder were
obtained under a materials transfer agreement with
GlaxoSmithKline (GSK, PA). The compounds were dis-
solved in dimethyl sulfioxide (DMSO, Sigma-Aldrich,
St. Louis, MO) to a stock concentration of 10 mM.
Cell lines and culturing
Human melanoma cell lines from the M series were
established from patient’s biopsies under the University
of California Los Angeles (UCLA) Institutional Review
Board approval IRB#02-08-067. Cell lines with in vitro
acquired resistance to vemurafenib were generated as
previously described [13] and labeled as the parental cell
line followed by “AR” for acquired resistance. Cells were
cultured in RPMI 1640 with L-glutamine (Mediatech
Inc., Manassas, VA) containing 10% fetal bovine serum
(FBS, Omega Scientific, Tarzana, CA) and 1% penicillin,
streptomycin and amphotericin (Omega Scientific). All cell
lines were mycoplasma free when periodically tested using
a Mycoalert Mycoplasma Detection Kit (Lonza, Rockland,
ME). Cell cultures were maintained at 37°C in a humidified
atmosphere of 5% CO2 and passaged into new flasks as
needed. Information of the mutational status of the cell
lines used in the study has been previously described [1].Growth assays
For short term growth assays, melanoma cell lines were
seeded in 96-well plates (3000 cells/well). The following
day, the cells were treated in duplicate with dabrafenib,
AKTi or the combination in 10-fold serial dilutions starting
from 10 μM for 72-120 hours depending on each cell
line’s specific growth rate. Cell viability was measured
by using the CellTiter-GLO® Luminescent Cell Viability
assay (Promega, Madison, WI). The IC50 values were de-
termined by interpolation from the dose-response curve.
Each experiment was repeated at least three times and the
average of minimum two is presented. In long term assays,
cells were seeded in 96-well plates (10,000 cells/well).
To study delays in emergence of resistance, the cells
were treated with 200 nM dabrafenib (2 × IC80 for
M397) alone or in combination with 2 nM trametinib
(2 × IC80 for M397) or the combination of all three
drugs including 2.5 μM AKTi. In another setup, cells
were treated with dabrafenib and trametinib at the
above mentioned concentrations and upon development
of resistance to these two drugs, trametinib was replaced
with 2.5 μM AKTi. Culture media containing the drugs
was changed once a week. Growth of the cells was moni-
tored and upon confluence of some wells, a gradient of the
cells were plated to be used as a reference for the cell num-
ber. One hour before cell viability was determined using a
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS)-based colorimetric cell proliferation assay (Promega)
the drug media was replaced with fresh culture media
without drugs to eliminate measurement of absorbance
of the drugs and to reduce the drugs impact on mito-
chondrial activity.
Western blotting
Cells were seeded in 12-well plates at a density of 200,000
cells/well. The next day, the culture medium was replaced
with media containing DMSO, 50 nM dabrafenib, 2.5 μM
AKTi or the combination. After 24 hours, the media was
removed and the cells were lysed directly in the wells for
15-20 min with lysis buffer (Pierce RIPA buffer, Thermo
Scientific) containing phosphatase- and protease inhibitors
(Sigma) and protein was extracted for western blot analysis
as previously described [19]. Blots were blocked and probed
with primary antibodies in 5% milk or 5% bovine serum
albumin (BSA) in 1% Tween-20 phosphate-buffered saline
(PBS-tween), washed with PBS-tween three times and incu-
bated with horse-radish-linked secondary antibodies. Pri-
mary antibodies included p-AKT Ser473 and Thr308, AKT,
p-S6K Thr389, S6K, p-S6 Ser235/236, S6, p-4EBP-1, 4EBP-1,
p-GSK-3β, GSK-3β and GAPDH (all from Cell Signaling
Technology, Danvers, MA). The immunoreactivity was visu-
alized by use of an ECL-2 kit (Pierce, Thermo Scientific) and
scanning of the blots by a Typhoon scanner (Amersham
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tein levels from western blot analysis was done using
ImageQuant software (version 5.2 Molecular dynamics).
Cell cycle and apoptosis analysis
Cells were seeded at a density of 200,000 cells/well in
6-well plates. The following day, the culture medium
was replaced by medium containing DMSO, 1 μM staur-
osporine (positive control for apoptosis), 50 nM dabrafe-
nib, 2.5 μM AKTi or the combination. After 48 hours of
exposure to the drugs, both adherent and floating cells were
harvested by trypsinization and fixed for 20 minutes with
Cytofix/Cytoperm solution (BD Biosciences, San Jose, CA).
For apoptosis, cells were stained with Alexa Flour700
linked anti-cleaved-PARP antibody (5 μL/ 1 × 106 cells,
BD biosciences) for 30 minutes. Next, for cell cycle analysis,
the cells were washed with Perm/Wash (BD Bioscience) be-
fore resuspended in 3 μM DAPI (Sigma-Aldrich) solution
diluted in PBS containing 1% bovine serum albumin at a
concentration of 1 × 106 cells/mL. Flow cytometry was per-
formed on a LSR-II (BD Bioscience) and data was analyzed
using FlowJo (PC version 7, Tree Star Inc, Asland, OR).
Cell death detection ELISA
Melanoma cell lines (5,000/well in 96-well plate) were
treated in triplicate with DMSO, 50 nM dabrafenib, 2.5 μM
AKTi or the combination for 48 hours. Apoptosis was
quantified by anti-body-mediated capture and detection
of cytoplasmic mononucleosome- and oligonucleosome-
associated histone-DNA complexes (Cell death Detection
ELISA plus kit, Roche) according to the manufacturer’s
instructions. Results were expressed as the average ab-
sorbance value of triplicates.
Statistical analysis
IC50 values were calculated on the basis of the growth
inhibition curves and define the concentration of drugs
that resulted in 50% growth inhibition. Synergistic, additive
or antagonistic effects of the drug combinations were
determined by the use of the combination index (CI)
method of Chou and Talalay using the Calcusyn software
(version 2.0 Biosoft, Cambrigde,UK). Any CI values less
than 1 indicates synergism, CI = 1 additive effect and CI > 1
antagonism. Error bars represent the standard error of
the mean (SEM). A two-tailed unpaired t-test was used
when applicable. P-values < 0.05 were considered to be
statistically significant.
Additional files
Additional file 1: Figure S1. Effects of single agent dabrafenib, AKTi
or the combination on cell proliferation and viability. Growth
inhibition curves of melanoma cell lines with differential sensitivity to
single agent dabrafenib and AKTi (A). Cells were treated withincreasing concentrations (1-10,000 nM) of dabrafenib, AKTi or the
combination for 72-120 hours to assess cell viability. The graphs
represent the average growth inhibition in percent of minimum two
independent experiments in duplicates and the error bars represent SEM.
Dose-effect parameters for the cell lines with synergy data (B). The r value is
the linear correlation coefficient of the median-effect plot while m denotes
the shape of the dose-effect curves.
Additional file 2: Figure S2. Quantitative analysis of p-S6 from western
blots. Data corresponds to the p-S6 bands in the western blots presented in
figure 4. The relative reduction in p-S6 in cell lines M411, M397, M414, M410
and M409AR corresponds with the response to the combined treatment,
with the more sensitive cell line M411 showing the highest reduction and
the resistant cell line M299 showing the slightest reduction in p-S6.
Additional file 3: Figure S3. Anti-cleaved-PARP gating strategy. The
fraction of anti-cleaved-PARP positive cells was determined by using an
unstained control. Apoptosis induced by staurosporine was used as a
positive control. The analysis was done by using FlowJo software
(PC ver. 7).
Additional file 4: Figure S4. Determining apoptosis using a cell death
detection ELISA. Cells were treated with DMSO, 50 nM dabrafenib, 2.5 μM
AKTi or the combination for 48 hours. The extent of apoptosis is reflected
by the enrichment of nucleosomes in the cytoplasm, which was
quantitated as the relative increase in absorbance (y-axis). The panel
included one cell line sensitive to both dabrafenib and AKTi (M411), one
cell line sensitive to AKTi but intermediate resistant to dabrafenib (M414)
and one cell line demonstrating resistance to both drugs (M299). The
bars represent the average absorbance of triplicates.
Additional file 5: Figure S5. Example of a standard curve used for the
calculations of cell number in long term culture. Cells were plated in 1:2
serial dilutions starting from 50,000 cells. The measured absorbance
(using a MTS-based assay) from these wells were plotted against the
known cell numbers and by use of the equation for the trend line
through (0.0) the unknown cell numbers could be determined.
Competing interests
AR has participated in scientific advisory boards from GSK. The honoraria
from these boards are paid to Institutional accounts at UCLA.
Authors’ contributions
AL, MA, DW, LR performed the experiments and AL co-wrote the manuscript.
MA participated in the design of the study and in the interpretation of data
and revised the manuscript critically. BCA designed the experiments performed
by flow cytometry and MC participated in collecting the data. AR conceived the
study and participated in its design and coordination and co-wrote the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was funded by NIH grant PO1 CA168585, The Seaver Institute, the
Dr. Robert Vigen memorial fund, the Louise Belley and Richard Schnarr Fund,
the Wesley Coyle Memorial Fund, the Garcia-Corsini Family Fund, the Bila
Alon Hacker Memorial Fund, the Fred L. Hartley Family Foundation, the Ruby
Family Foundation, the Jonsson Cancer Center Foundation, and the
Caltech-UCLA Joint Center for Translational Medicine (to A.R.).
Author details
1Department of Medicine, Division of Hematology-Oncology, David Geffen
School of Medicine, University of California Los Angeles (UCLA), Los Angeles,
CA, USA. 2Department of Surgery, Division of Surgical Oncology, David Geffen
School of Medicine, University of California Los Angeles (UCLA), Los Angeles,
CA, USA. 3Department of Molecular and Medical Pharmacology, David Geffen
School of Medicine, University of California Los Angeles (UCLA), Los Angeles,
CA, USA. 4Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles,
CA, USA. 5Department of Medicine, Division of Hematology-Oncology, 11-934
Factor Building, Jonsson Comprehensive Cancer Center at UCLA, 10833 Le
Conte Avenue, Los Angeles, CA 90095-1782, USA.
Received: 25 September 2013 Accepted: 25 March 2014
Published: 16 April 2014
Lassen et al. Molecular Cancer 2014, 13:83 Page 13 of 14
http://www.molecular-cancer.com/content/13/1/83References
1. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H,
MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE,
Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A:
Differential sensitivity of melanoma cell lines with BRAFV600E mutation
to the specific Raf inhibitor PLX4032. J Transl Med 2010, 8:39.
2. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C,
Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B,
Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su
F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo
J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature 2010, 467:596–599.
3. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski
P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C,
Chiarion-Sileni V, Martin A-M, Swann S, Haney P, Mirakhur B, Guckert ME,
Goodman V, Chapman PB: Dabrafenib in BRAF-mutated metastatic
melanoma: a multicentre, open-label, phase 3 randomised controlled
trial. Lancet 2012, 380:358–365.
4. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur
GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D,
Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye
F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A: Survival in BRAF V600-mutant
advanced melanoma treated with vemurafenib. N Engl J Med 2012,
366:707–714.
5. Fedorenko IV, Paraiso KH, Smalley KS: Acquired and intrinsic BRAF inhibitor
resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 2011,
82:201–209.
6. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar
N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS:
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
N-RAS upregulation. Nature 2010, 468:973–977.
7. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T,
Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas
A, Lo RS: Melanoma whole-exome sequencing identifies (V600E)B-RAF
amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun
2012, 3:724.
8. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H,
Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT,
Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS,
Rosen N, Solit DB: RAF inhibitor resistance is mediated by dimerization of
aberrantly spliced BRAF(V600E). Nature 2011, 480:387–390.
9. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA,
Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H,
Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S,
Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty
KT, Dummer R, Weber BL, et al: COT drives resistance to RAF inhibition
through MAP kinase pathway reactivation. Nature 2010, 468:968–972.
10. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM,
Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA:
Dissecting therapeutic resistance to RAF inhibition in melanoma by
tumor genomic profiling. J Clin Oncol 2011, 29:3085–3096.
11. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C,
Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers
WR, Dummer R, Garraway LA: MEK1 mutations confer resistance to MEK and
B-RAF inhibition. Proc Natl Acad Sci U S A 2009, 106:20411–20416.
12. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O,
Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G,
Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P,
Allred A, Ouellet D, Kim KB, Patel K, Weber J: Combined BRAF and MEK
inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012,
367:1694–1703.
13. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B,
Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A: Reversing melanoma
cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR
pathway. PLoS One 2011, 6:e28973.
14. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H:
Acquired resistance to BRAF inhibition can confer cross-resistance to
combined BRAF/MEK inhibition. J Invest Dermatol 2012, 132:1850–1859.
15. Shi H, Kong X, Ribas A, Lo RS: Combinatorial treatments that overcome
PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF
inhibition. Cancer Res 2011, 71:5067–5074.16. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla
AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R,
D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA,
Sosman JA, Nathanson KL, Herlyn M: Acquired resistance to BRAF inhibitors
mediated by a RAF kinase switch in melanoma can be overcome by
cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683–695.
17. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz
D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J,
Jorgensen C, Marais R: Inhibiting EGF receptor or SRC family kinase
signaling overcomes BRAF inhibitor resistance in melanoma.
Cancer Discov 2013, 3:158–167.
18. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G,
Herlyn M: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways
present molecular targets for the effective treatment of advanced
melanoma. Front Biosci 2005, 10:2986–3001.
19. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E,
Garbe C, Meier FE: Combined inhibition of MAPK and mTOR signaling
inhibits growth, induces cell death, and abrogates invasive growth of
melanoma cells. J Invest Dermatol 2008, 128:2013–2023.
20. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A,
Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J,
Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin Invest
2008, 118:3065–3074.
21. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS,
Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A,
Mangold GL, Patnaik A: The clinical effect of the dual-targeting strategy
involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with
advanced cancer. Clin Cancer Res 2012, 18:2316–2325.
22. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K,
Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski
J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G: Resistance to
selective BRAF inhibition can be mediated by modest upstream
pathway activation. Cancer Res 2012, 72:969–978.
23. Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F,
Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey
JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del
Bufalo D, Milella M: The mitogen-activated protein kinase (MAPK) cascade
controls phosphatase and tensin homolog (PTEN) expression through
multiple mechanisms. J Mol Med (Berl) 2012, 90:667–679.
24. Aksamitiene E, Kiyatkin A, Kholodenko BN: Cross-talk between mitogenic
Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc
Trans 2012, 40:139–146.
25. Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu H: BRAFV600E negatively
regulates the AKT pathway in melanoma cell lines. PLoS One 2012, 7:e42598.
26. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA:
Basal and treatment-induced activation of AKT mediates resistance to
cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous
melanoma cells. Cancer Res 2010, 70:8736–8747.
27. Carracedo A, Pandolfi PP: The PTEN-PI3K pathway: of feedbacks and
cross-talks. Oncogene 2008, 27:5527–5541.
28. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE,
Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino
MC, Stivala F, Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv Enzyme
Regul 2006, 46:249–279.
29. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy
JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A: Combination
therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma
cell lines with distinct driver mutations. J Transl Med 2011, 9:76.
30. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM:
Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis.
Lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533–33539.
31. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC:
Cleavage of poly(ADP-ribose) polymerase by a proteinase with
properties like ICE. Nature 1994, 371:346–347.
32. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer
PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated,
activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809–819.
33. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M,
Schittek B: Combined targeting of MAPK and AKT signalling pathways is
Lassen et al. Molecular Cancer 2014, 13:83 Page 14 of 14
http://www.molecular-cancer.com/content/13/1/83a promising strategy for melanoma treatment. Br J Dermatol 2007,
156:1204–1213.
34. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M: Multiple
signaling pathways must be targeted to overcome drug resistance in
cell lines derived from melanoma metastases. Mol Cancer Ther 2006,
5:1136–1144.
35. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM,
Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran
S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA: TORC1
Suppression Predicts Responsiveness to RAF and MEK Inhibition in
BRAF-Mutant Melanoma. Sci Transl Med 2013, 5:196ra198.
36. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA: Role and
therapeutic potential of PI3K-mTOR signaling in de novo resistance to
BRAF inhibition. Pigment Cell Melanoma Res 2012, 25:248–258.
37. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H,
Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF:
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via
regulation of IRS proteins. J Cell Biol 2004, 166:213–223.
38. Mora A, Komander D, van Aalten DM, Alessi DR: PDK1, the master
regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004,
15:161–170.
39. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R,
Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA,
Sosman JA, van Baren N, Long GV, Ribas A, Lo RS: Acquired Resistance and
Clonal Evolution in Melanoma during BRAF Inhibitor Therapy.
Cancer Discov 2014, 4:80–93.
40. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM,
Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M,
McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger
SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B,
Hassel JC, Gabriel SB, Carter SL, Getz G, et al: The Genetic Landscape of
Clinical Resistance to RAF Inhibition in Metastatic Melanoma.
Cancer Discov 2014, 4:94–109.
41. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner
A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K,
Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E,
Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA,
Garraway LA: MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma
Patients with Acquired Resistance to Combined RAF/MEK Inhibition.
Cancer Discov 2014, 4:61–68.
doi:10.1186/1476-4598-13-83
Cite this article as: Lassen et al.: Effects of AKT inhibitor therapy in
response and resistance to BRAF inhibition in melanoma. Molecular
Cancer 2014 13:83.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
